Form 6-K Summary
Issuer identified in filing: I-MAB, not Novabridge Biosciences. The filing is a Form 6-K for the month of October 2021, filed October 4, 2021, by a foreign private issuer that files annual reports on Form 20-F.
Business Context and Reporting Period
The filing cover page identifies I-MAB, with principal executive offices in Shanghai, People’s Republic of China. Commission file number: 001-39173. The filing references Exhibit 99.1, described as a press release, but the press release text is not included in the provided source.
Financial Metrics
The provided filing text does not include revenue, profit or loss, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Changes Versus Prior Period
The provided text does not disclose material changes versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The provided text does not contain guidance, outlook, management commentary, risk factors, contingencies, or unusual items. Any substantive disclosure may be contained in the referenced Exhibit 99.1, which was not provided.
Investor Verification Items
- Confirm the issuer identity; the filing names I-MAB, while the request metadata names Novabridge Biosciences.
- Obtain and review Exhibit 99.1, the referenced press release.
- Verify whether the October 2021 filing includes any financial, clinical, corporate, or market-related disclosures in the omitted exhibit.
- Confirm the issuer’s Form 20-F reporting status and commission file number 001-39173.